Abstract:The serotonin 1A receptor has been linked to both the pathophysiology of major depressive disorder (MDD) and the antidepressant action of serotonin reuptake inhibitors. Most PET studies of the serotonin 1A receptor in MDD used the receptor antagonist radioligand, [carbonyl- C]WAY100635; however the interpretation of the combined results has been contentious owing to reports of higher or lower binding in MDD with different outcome measures. The reasons for these divergent results originate from several sources, including properties of the radiotracer itself, which complicate its quantification and interpretation; as well as from previously reported differences between MDD and healthy volunteers in both reference tissue binding and plasma free fraction, which are typically assumed not to differ. Recently, we have developed two novel hierarchical multivariate methods which we validated for the quantification and analysis of [ C]WAY100635, which show better accuracy and inferential efficiency compared to standard analysis approaches. Importantly, these new methods should theoretically be more resilient to many of the factors thought to have caused the discrepancies observed in previous studies. We sought to apply these methods in the largest [ C]WAY100635 sample to date, consisting of 160 individuals, including 103 MDD patients, of whom 50 were not-recently-medicated and 53 were antidepressant-exposed, as well as 57 healthy volunteers. While the outcome measure discrepancies were substantial using conventional univariate analysis, our multivariate analysis techniques instead yielded highly consistent results across PET outcome measures and across pharmacokinetic models, with all approaches showing higher serotonin 1A autoreceptor binding potential in the raphe nuclei of not-recently-medicated MDD patients relative to both healthy volunteers and antidepressant-exposed MDD patients. Moreover, with the additional precision of estimates afforded by this approach, we can show that while binding is also higher in projection areas in this group, these group differences are approximately half of those in the raphe nuclei, which are statistically distinguishable from one another. These results are consistent with the biological role of the serotonin 1A autoreceptor in the raphe nuclei in regulating serotonin neuron firing and release, and with preclinical and clinical evidence of deficient serotonin activity in MDD due to over expression of autoreceptors resulting from genetic and/or epigenetic effects. These results are also consistent with downregulation of autoreceptors as a mechanism of action of selective serotonin reuptake inhibitors. In summary, the results using multivariate analysis approaches therefore demonstrate both face and convergent validity, and may serve to provide a resolution and consensus interpretation for the disparate results of previous studies examining the serotonin 1A receptor in MDD.

Non-displaceable binding potential changes of striatal dopamine D2 receptors in patients with first-episode major depressive disorder and the correlation with clinical features

Molecular Imaging of Striatal Dopamine Transporters in Major Depression—a Meta-Analysis

Decoupling of Dopamine Release and Neural Activity in Major Depressive Disorder during Reward Processing Assessed by Simultaneous fPET-fMRI

PET Imaging of the Serotonin 1A Receptor in Major Depressive Disorder: Hierarchical Multivariate Analysis of [ C]WAY100635 Overcomes Outcome Measure Discrepancies

Reduced Nucleus Accumbens Functional Connectivity in Reward Network and Default Mode Network in Patients with Recurrent Major Depressive Disorder.

Distinctive Pretreatment Features of Bilateral Nucleus Accumbens Networks Predict Early Response to Antidepressants in Major Depressive Disorder

Resting-State fMRI in Predicting Response to Treatment With SSRIs in First-Episode, Drug-Naive Patients With Major Depressive Disorder

Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study.

Regional Cerebral Metabolism Alterations Affect Resting-State Functional Connectivity in Major Depressive Disorder.

Abnormal Striatum Functional Connectivity in Major Depressive Disorder: a Resting State Functional Magnetic Resonance Imaging Study

Higher 5-HT1A Receptor Binding Potential During a Major Depressive Episode Predicts Poor Treatment Response: Preliminary Data from a Naturalistic Study

High-field Magnetic Resonance Imaging of Structural Alterations in First-Episode, Drug-Naive Patients with Major Depressive Disorder

Changes of dopamine transporters in major depression and Parkinson disease

Pretreatment predictors of early response revealed by quantitative cerebral blood flow in major depressive disorder

Effects of deep brain stimulation on dopamine D2 receptor binding in patients with treatment-refractory depression

Secondary analysis of neurotransmitter metabolism and cognitive function in first-diagnosed, drug-naïve adult patients with major depressive disorder

Characterization of Resting-State Striatal Differences in First-Episode Depression and Recurrent Depression

A multi-site 99m Tc-HMPAO SPECT study of cerebral blood flow in a community sample of patients with major depression

Structural and functional alterations in untreated patients with major depressive disorder and bipolar disorder experiencing first depressive episode: A magnetic resonance imaging study combined with follow-up

Duloxetine Effects on Striatal Resting-State Functional Connectivity in Patients with Major Depressive Disorder.

Cerebral Metabolism in Major Depressive Disorder: a Voxel-Based Meta-Analysis of Positron Emission Tomography Studies